With years of research in Glycoengineering, CD BioGlyco has accumulated extensive experience. We have successfully developed efficient and stable plant, mammalian, and fungal expression systems to meet our clients' glycoprotein production needs.
Glycosylation is the process of attaching carbohydrates to proteins or lipids under the control of enzymes. Two main types of glycosylation are common: 1) N-glycosylation (attached to the nitrogen of the asparagine or arginine side chain); 2) O-glycosylation (attached to the hydroxyl oxygen of serine, threonine, tyrosine, hydroxylysine, or hydroxyproline side chain). Most secreted proteins in eukaryotes are modified by glycosylation. The number and structure of glycans affect protein folding, intracellular trafficking, and solubility. Therefore, glycosylation has a huge impact on the biological activity of glycoprotein and we should control carefully it during the manufacturing process to achieve optimal therapeutic effects.
During glycosylation, glycans mature in a species-dependent or tissue-dependent manner. The glycosylation patterns of glycoproteins vary greatly depending on the host species, cell type, and physiological state. Therefore, the host-specific differences of glycans are particularly important. Different mature glycan structures are obtained when the same polypeptide is expressed in different hosts. Current expression platforms for glycoprotein drugs generally do not produce homogeneous glycans, which easily leads to adverse side effects. Therefore, in recent years, scientists have made a lot of efforts to apply glycoengineering techniques to different expression systems to produce homogeneous therapeutic glycoproteins.
Fig.1 Overview of glycoengineering strategies. (Narimatsu, et al., 2021)
Glycoengineering of expression systems is increasingly recognized as an important strategy for improving glycoprotein drugs. For better production of homogeneous recombinant glycoproteins, CD BioGlyco has applied glycoengineering to mammalian cells, Pichia pastoris, plant, and insect cell expression systems. Our mammalian expression systems include human cell lines, Chinese hamster ovary cells (CHO), and small hamster kidney cells (BHK). We apply glycoengineering techniques to the N. benthamiana expression system to generate target glycoproteins. In addition, we also provide clients with high-quality glycoengineered-Pichia pastoris expression system.
We provide human cell lines, CHO cells, and BHK cells for glycoprotein production. The system greatly increases the output on the premise of ensuring product stability.
We knock out the och1 gene and introduce mannosidase by glycoengineering technology to construct a first-class glycoengineered Pichia expression system to overcome the excessive glycosylation of the protein.
CD BioGlyco is a leading service provider specializing in efficient and stable glycoengineered expression systems. We have plant, mammalian, and fungal expression vectors for glycoprotein production. If you are interested in our glycoengineered expression systems, please contact us for more information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.